Page 12 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SAN FRANCISCO and SUZHOU, China, June 27, 2021 /PRNewswire/  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) as a first-line treatment for people with advanced or unresectable hepatocellular carcinoma (HCC). This is the first regulatory approval of a PD-1 inhibitor-based combination therapy for the first-line treatment for HCC.

United statesHong kongAdimab incyteYongjun liuEli lillyZhongshan hospital of fudan universityMd anderson cancer centerData monitoring committeeNational medical products administrationChina national reimbursement drug listIncyte corporationRadiographic review committeeInnovent biologics incInnovent biologicsNew drug applicationIndependent data monitoring committee